News of Note—Vaccine exemption 'hot spots,' NIAID’s RSV vaccine study and more


Here is some other vaccine news of note for the week.

> Some regions in the 18 states that allow parents to opt their children out of school immunization requirements for nonmedical reasons could be vulnerable to vaccine-preventable diseases, a new study shows. The Washington Post article

> The National Institute of Allergy and Infectious Diseases (NIAID) has started a human study of an intranasal vaccine against respiratory syncytial virus (RSV). Release

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

> Combining a pre-erythrocytic malaria vaccine like GlaxoSmithKline’s Mosquirix with a transmission-blocking vaccine, which prevents mosquitoes from transferring the parasites, could boost protection to around 91%, a study in mice shows. Release

> Adel Mahmoud, M.D., Ph.D., who was president of Merck Vaccines from 1998 to 2006, died on June 11. He oversaw the creation of HPV vaccine Gardasil, rotavirus vaccine RotaTeq, shingles vaccine Zostavax, and measles, mumps, rubella and chicken pox combo shot ProQuad. The New York Times article

Suggested Articles

An FDA panel gave Sanofi's Dengvaxia a mixed endorsement, voting down its use in people 17 and older.

Prosecutors in the Philippines have found probable cause to indict six Sanofi officials for its Dengvaxia rollout.

The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.